Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report on Form 10-K for Year Ending Dec. HTML 1.05M
31, 2016
2: EX-4.6 Form of Warrant Dated July 20, 2016 HTML 107K
3: EX-4.7 Contingent Common Stock Purchase Warrant HTML 72K
4: EX-4.8 Emmanuel Warrant Issued on November 10, 2013 HTML 87K
5: EX-4.9 Emmanuel Warrant HTML 74K
6: EX-10.26 2017 Employment Agreement - Daniel Levitt, M.D., HTML 101K
Ph.D.
7: EX-10.29 2017 Employment Agreement - Scott Wieland HTML 79K
8: EX-10.30 2017 Employment Agreement - John Caloz HTML 79K
9: EX-10.31 2017 Employment Agreement - Olivia Ware HTML 81K
10: EX-10.38 2017 Amendment to Employment Agreement - Steven A. HTML 30K
Kriegsman
11: EX-10.39 Restricted Stock Purchase Agreement Dated January HTML 46K
11, 2017
12: EX-23.1 Consent of Independent Accounting Firm HTML 23K
13: EX-31.1 Certification of Chief Executive Officer HTML 30K
14: EX-31.2 Certification of Chief Financial Officer HTML 29K
15: EX-32.1 Certification of Chief Executive Officer (SEC. HTML 24K
1350)
16: EX-32.2 Certification of Chief Financial Officer (SEC. HTML 25K
1350)
23: R1 Document and Entity Information HTML 51K
24: R2 Balance Sheets HTML 101K
25: R3 Balance Sheets (Parenthetical) HTML 51K
26: R4 Statements of Operations HTML 66K
27: R5 Statements of Stockholders' Equity HTML 118K
28: R6 Statements of Cash Flows HTML 128K
29: R7 Nature of Business HTML 34K
30: R8 Summary of Significant Accounting Policies HTML 83K
31: R9 Foreign Currency Remeasurement HTML 29K
32: R10 Receivables HTML 28K
33: R11 Prepaid and Other Assets HTML 25K
34: R12 Short-term Investments HTML 28K
35: R13 Equipment and Furnishings HTML 34K
36: R14 Accrued Expenses and Other Current Liabilities HTML 34K
37: R15 Non-Cash Litigation Settlement Due in Shares of HTML 26K
Common Stock
38: R16 Term Loan HTML 41K
39: R17 Warrant Liabilities HTML 41K
40: R18 Commitments and Contingencies HTML 62K
41: R19 Equity Transactions HTML 36K
42: R20 Stock Options and Equity-Classified Warrants HTML 218K
43: R21 Stockholder Protection Rights Plan HTML 28K
44: R22 Income Taxes HTML 66K
45: R23 Earnings (Loss) Per Share HTML 31K
46: R24 Quarterly Financial Data (Unaudited) HTML 49K
47: R25 Subsequent Event HTML 25K
48: R26 Schedule Ii - Valuation and Qualifying Accounts HTML 42K
49: R27 Summary of Significant Accounting Policies HTML 132K
(Policies)
50: R28 Summary of Significant Accounting Policies HTML 53K
(Tables)
51: R29 Equipment and Furnishings (Tables) HTML 32K
52: R30 Accrued Expenses and Other Current Liabilities HTML 34K
(Tables)
53: R31 Term Loan (Tables) HTML 42K
54: R32 Warrant Liabilities (Tables) HTML 39K
55: R33 Commitments and Contingencies (Tables) HTML 46K
56: R34 Stock Options and Equity-Classified Warrants HTML 219K
(Tables)
57: R35 Income Taxes (Tables) HTML 62K
58: R36 Earnings (Loss) Per Share (Tables) HTML 29K
59: R37 Quarterly Financial Data (Unaudited) (Tables) HTML 48K
60: R38 Nature of Business (Details) HTML 68K
61: R39 Summary of Significant Accounting Policies HTML 69K
(Details)
62: R40 Foreign Currency Remeasurement (Details) HTML 27K
63: R41 Receivables (Details) HTML 26K
64: R42 Prepaid and Other Assets (Details) HTML 26K
65: R43 Short-term Investments (Details) HTML 25K
66: R44 Equipment and Furnishings (Details) HTML 35K
67: R45 Accrued Expenses and Other Current Liabilities HTML 38K
(Details)
68: R46 Non-Cash Litigation Settlement Due in Shares of HTML 30K
Common Stock (Details)
69: R47 Term Loan (Details) HTML 75K
70: R48 Warrant Liabilities (Details) HTML 47K
71: R49 Commitments and Contingencies (Details) HTML 107K
72: R50 Equity Transactions (Details) HTML 111K
73: R51 Stock Options and Equity-Classified Warrants HTML 199K
(Details)
74: R52 Stock Options and Equity-Classified Warrants, HTML 37K
Schedule of Employee and Non Employee Service
Share Based Compensation (Details)
75: R53 Stock Options and Equity-Classified Warrants, HTML 87K
Options by Exercise Price Range (Details)
76: R54 Stock Options and Equity-Classified Warrants, HTML 76K
Warrants, Shares Purchased and Intrinsic Value
(Details)
77: R55 Stockholder Protection Rights Plan (Details) HTML 36K
78: R56 Income Taxes (Details) HTML 113K
79: R57 Earnings (Loss) Per Share (Details) HTML 40K
80: R58 Quarterly Financial Data (Unaudited) (Details) HTML 35K
81: R59 Subsequent Event (Details) HTML 32K
82: R60 Schedule Ii - Valuation and Qualifying Accounts HTML 35K
(Details)
84: XML IDEA XML File -- Filing Summary XML 127K
83: EXCEL IDEA Workbook of Financial Reports XLSX 78K
18: EX-101.INS XBRL Instance -- cytr-20161231 XML 2.03M
20: EX-101.CAL XBRL Calculations -- cytr-20161231_cal XML 209K
21: EX-101.DEF XBRL Definitions -- cytr-20161231_def XML 648K
17: EX-101.LAB XBRL Labels -- cytr-20161231_lab XML 1.78M
22: EX-101.PRE XBRL Presentations -- cytr-20161231_pre XML 1.03M
19: EX-101.SCH XBRL Schema -- cytr-20161231 XSD 178K
85: ZIP XBRL Zipped Folder -- 0000799698-17-000012-xbrl Zip 193K
‘EX-32.2’ — Certification of Chief Financial Officer (SEC. 1350)
This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the "Company") hereby certifies that:
(i) the accompanying Annual Report on Form 10-K of
the Company for the year ended
December 31, 2016 (the
"Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
the Company.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-K and shall not be considered filed as part of the Form 10-K.
